Please login to the form below

Not currently logged in

Eisai and UCB give epilepsy updates

Eisai and UCB have revealed the results of studies at the International Epilepsy Congress in Rome

Japanese pharmaceutical company Eisai has presented new data on its epilepsy drugs, notably for its investigational drug perampanel and Zonegran, at the International Epilepsy Congress in Rome.

In a 389-patient phase III study of the drug perampanel, patients with partial-onset seizures who took the drug in 8mg and 12mg doses showed statistically significant reductions in median seizure frequency compared with those who took the placebo while receiving treatment with one to three other epilepsy drugs.

Study 305 found that 14.7 per cent of patients taking the placebo showed a reduction in seizure frequency by 50 per cent or more, compared with 33.3 per cent of patients taking perampanel in the 8mg strength and 33.9 per cent of those taking 12mg doses.

Also, while patients in the placebo group showed a reduction in median seizure frequency of 9.7 per cent, those taking perampanel in the 8mg strength once per day showed a reduction of 30.5 per cent, while those taking it the 12mg strength once daily showed a 17.6 per cent reduction.

Eisai also unveiled preliminary results from a new phase III paediatrics study which showed that Zonegran (zonisamide) is more effective than placebo and well tolerated in children with partial-onset seizures treated with one or two other anti-epileptic drugs (AEDs).

The results showed that significantly more patients responded positively to treatment with zonisamide (50.5 per cent) versus treatment with placebo (31 per cent).

Meanwhile UCB also presented results of a new study that have shown that overall US healthcare costs for epilepsy patients with unstable AED treatment during a two-year period were at least twice those of patients on stable treatment.

The study followed 12,718 patients with epilepsy taking one or more AEDs during a two-year period. Overall healthcare costs for patients with an AED switch ($28,732) or add-on ($31,321) were two times or more higher than the overall healthcare costs for patients on stable treatment ($11,505). Emergency room costs for patients with unstable AED treatment were approximately three to eight times higher than for those on stable therapy ($1,176).

Find out more about the International Epilepsy Congress.

31st August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...